QRS Music Technologies, Inc.
15.7.2021 14:02:37 CEST | ACCESS Newswire | Press release
The company filed its application with the OTC Markets to become a Pink Sheets reporting company.
SENECA, PA / ACCESSWIRE / July 15, 2021 / QRS Music Technologies, Inc. (OTC PINK:QRSM), a leader in the design, manufacture and distribution of audio, digital and multimedia products, music content, piano technologies, Story & Clark pianos, and other digital audio accessories, is pleased to release the following Shareholder Update.
The company filed its application with the OTC Markets to become a Pink Sheets reporting company. The Company is working with its PCAOB auditing firm to prepare the appropriate annual financial statements for reporting in September. This initiative to upgrade to the next level, OTCBB, positions the Company and its business focus closer to achieving its ultimate trading and growth goals.
QRS Music Technologies, Inc. (OTCB:QRSM) is a leader in the design, manufacture and distribution of digital music technologies, pianos and piano accessories. Brands include PNOmation®, PNOscan®, PNOtouch, Sync-Along, QRS-Connect, and Story & Clark Pianos. QRS also manufactures and distributes other unique musical instrument digital interface (MIDI) technologies and novelties. QRS offers market-focused solutions for artists, composers, teachers, home, hospitality and education. QRS continues to innovate with patented and patent-pending music content and music content delivery technologies. QRS, since its founding in 1900, keeps alive a slice of Americana - player piano music roll production and creation. QRS is the creator of Pianomation®, now PNOmation, the first MIDI system to combine analog and digital technology to turn any piano into a reproducing player piano.
QRS Music was founded in 1900 and is based in Seneca, Pennsylvania. Additional information about QRS is available at www.qrsmusic.com, 1-800-247-6557 and text at 814-676-6683.
Forward-Looking Statements
Statements made in this news release that relate to future plans, events or performances are forward-looking statements. Any statements containing words, such as 'believes,' 'should,' 'anticipates,' 'plans' or 'expects,' as well as other statements, are forward-looking and those statements involve risks and uncertainties outside of the control of QRS and are based on current expectations. Consequently, actual results could differ materially from the expectations expressed in these forward-looking statements.
Media Contact:
Parker Welch
814-493-6538
parkerw@qrsinc.com
SOURCE: QRS Music Technologies, Inc.
View source version on accesswire.com:
https://www.accesswire.com/655564/QRS-Music-Technologies-Inc-Announces-Shareholder-Update
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Anew Climate Expands European Forest Carbon Portfolio Through Ten-Year Agreement with Sweden's EKEN1.10.2026 15:00:00 CEST | Press release
HOUSTON, TX / ACCESS Newswire / October 1, 2026 / Anew Climate (Anew), one of the world's largest developers and marketers of carbon credits, announced a ten-year agreement with EKEN Financing Value Added Forestry (EKEN) to bring Swedish improved forest management (IFM) credits to corporate buyers worldwide. The agreement extends Anew's European forest carbon portfolio, which it maintains alongside millions of acres of managed forestland across North America. Under the collaboration, Anew will serve as the exclusive commercialization partner for credits generated from projects developed by EKEN, handling purchaser engagements, structuring, and portfolio integration for corporate buyers in Europe and internationally. EKEN is preparing the project for development under VM0045, Verra's methodology for improved forest management using dynamic matched baselines from national forest inventories. While many conventional forest carbon baselines rest on a projection of what a landowner would hy
Karbon‑X (OTCQB:KARX) Reports Record Fiscal 2026 Revenue of $55.9 Million as Company Scales Global Carbon Market Operations1.10.2026 14:30:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / October 1, 2026 / Karbon‑X Corp. (OTCQB:KARX) ("Karbon‑X" or the "Company"), a vertically integrated climate solutions company operating across global carbon markets, today reported financial and operational results for the fiscal year ended May 31, 2026, reflecting a significant increase in operating scale across its carbon credit trading and project development activities. Karbon‑X generated record fiscal 2026 revenue of $55.9 million, compared with $3.16 million in fiscal 2025, representing an increase of approximately 1,670% year over year. Gross profit was $0.86 million, compared with $0.80 million in the prior year. Fiscal 2026 results reflected a shift in revenue mix toward high-volume, lower-margin trading activity as Karbon‑X completed its first full year of large-scale carbon credit trading. "Fiscal 2026 moved Karbon-X into a new stage of commercial growth," said Chad Clovis, Chief Executive Officer of Karbon-X. "Revenue reached nearly eighteen
Surmodics Acquires Alta Biomed Business, Expanding Hemocompatible Surface Technology and Analytical Testing Capabilities1.10.2026 14:00:00 CEST | Press release
HORSHAM, PA / ACCESS Newswire / October 1, 2026 / Surmodics Inc., a leading provider of surface technologies and performance coatings for the medical device industry, today announced that it has acquired the business of Alta Biomed, a Carlsbad, California-based medical device coating and testing services company specializing in surface technologies for vascular and other medical devices. The acquisition is a strategic addition to Surmodics' growing portfolio of hemocompatible and biocompatible surface technologies. It brings Alta Biomed's proprietary PzF™ thin-film surface modification technology to Surmodics, adding an established anti-thrombotic, anti-inflammatory and pro-healing option that joins Surmodics' existing hemocompatible portfolio. "As medical device innovation advances in neuromodulation, brain-computer interfaces, neurovascular, structural heart, and venous and arterial technologies, engineers and scientists need a broader range of surface technology options to address i
PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis30.9.2026 19:00:00 CEST | Press release
PRINCETON, NJ / ACCESS Newswire / September 30, 2026 / PharmaNest, Inc. an AI-enabled digital pathology company specializing in the quantitative and spatial characterization of fibrosis and Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, today announced a collaboration to integrate advanced digital pathology into Mediar's ongoing EncompaSSc Phase 2 clinical trial of MTX-474 in patients with diffuse cutaneous systemic sclerosis (dcSSc). MTX-474 is a first-in-class human IgG1 monoclonal antibody designed to neutralize EphrinB2 signaling, a pathway implicated in myofibroblast activation, extracellular matrix (ECM) deposition and tissue remodeling known to drive fibrosis in SSc. The randomized, double-blind, placebo-controlled EncompaSSc Phase 2 study is evaluating the safety and efficacy of MTX-474 in patients with dcSSc. Under the collaboration, PharmaNest will apply its FibroNest™ AI-enabled digital path
Innodata Opens Motion-Capture AI Lab to Help Humanoids Move Like Humans30.9.2026 15:50:00 CEST | Press release
NEW YORK, NY / ACCESS Newswire / September 30, 2026 / Innodata Inc. (Nasdaq:INOD) today announced the opening of a new R&D laboratory that is designed to generate the data needed to train the next generation of human-like robots and independently validate the performance data that robots generate internally. Innodata developed the lab in collaboration with Vicon, a leader in motion capture who consulted on the lab design and continues to provide technical consulting. The New Jersey-based lab is equipped with high-precision, low-latency infrared optical tracking cameras that measure movement down to the sub-millimeter level-a degree of accuracy that methods such as wearable inertial measurement unit (IMU) sensors and single-camera (monocular) video analysis typically cannot match. The lab addresses an urgent need for high-quality training data for humanoids, industrial robots, and other forms of physical AI. While many other data providers infer 3D motion by analyzing 2D video, Innodata
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom